Cash-rich BioNTech broadens scope as COVID shot sales slide

0
136
Vials labelled “VACCINE Coronavirus COVID-19” and a syringe are seen in front of a displayed Biontech logo in this illustration taken December 11, 2021. REUTERS/Dado Ruvic/Illustration

Summary

  • Q1 net profit 502 mln euros vs year earlier 3.7 bln
  • Fall comes as WHO declares global COVID emergency over
  • BioNTech says talks over EU vaccine contract continue

FRANKFURT, May 8 (Reuters) – Germany’s BioNTech (22UAy.DE), Pfizer’s (PFE.N) partner on COVID-19 vaccines, said on Monday its first-quarter net income plunged on lower demand for the shots as it widens its work on cancer and other diseases.

Reporting by Ludwig Burger and Patricia Weiss, Editing by Rachel More
-Advertisement-

RELATED ARTICLESMORE FROM AUTHOR